机构:[1]Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.[2]Department of General Surgery, Xuan Wu Hospital, Capital Medical University, Beijing, China.普通外科首都医科大学宣武医院[3]Department of Central Laboratory, Capital Medical University, Beijing, China.
BackgroundActivation of CXCL12/CXCR4 axis has been found to be associated with invasion and metastasis in many cancers. However, the underlying mechanism remains elusive. Increasing data highlight that non-coding RNAs are linked to CRC progression.MethodsThe effects of CXCR4 were investigated using villin-CXCR4 transgenic mice model by flow cytometry assay, immunohistochemistry, and Western blot. The mechanism was explored through bioinformatics, luciferase reporter assay and RNA immunoprecipitation assay.ResultsWe found that high CXCR4 expression exacerbated colitis-associated cancer in villin-CXCR4 transgenic mice. CXCR4(+/-)Apc(min/+) compound mutant mice demonstrated higher colorectal tumorigenesis than Apc(min/+) mice. Furthermore, overexpression of CXCR4 was found to promote the epithelial-mesenchymal transition (EMT) and infiltration of myeloid-derived suppressor cells (MDSCs) and macrophages in colonic tissue, accelerating colitis-associated and Apc mutation-driven colorectal tumorigenesis and progression. Notably, miR-133a-3p was found to be significantly decreased in HCT116 cells overexpressing CXCR4 by miRNA sequencing. miR-133a-3p was proved to target RhoA, which is involved in cytoskeletal reorganization that drive cell motility. Importantly, CXCL12/CXCR4-induced upregulation of lncRNA XIST functioned as a ceRNA to sponge miR-133a-3p, thereby liberating the repression of RhoA by miR-133a-3p. The negative correlation of miR-133a-3p with RhoA was also confirmed in human CRC tissues and CXCR4(+/-) mice.ConclusionsOur findings revealed the critical role of CXCR4 in promoting progression of inflammatory colorectal cancer through recruiting immunocytes and enhancing cytoskeletal remodeling by lncRNA XIST/ miR-133a-3p/ RhoA signaling. These results provide novel potential therapeutic targets for hindering CXCL12/CXCR4-induced CRC progression.
基金:
National Natural Science Foundation [81201731, 91629303]; Beijing Natural Science Foundation [7162024]; Basic and Clinical grants of Capital Medical University [16 JL56]
第一作者机构:[1]Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.
通讯作者:
通讯机构:[1]Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.
推荐引用方式(GB/T 7714):
Xinfeng Yu,Dong Wang,Xiaohui Wang,et al.CXCL12/CXCR4 promotes inflammation-driven colorectal cancer progression through activation of RhoA signaling by sponging miR-133a-3p[J].JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH.2019,38(1):32.doi:10.1186/s13046-018-1014-x.
APA:
Xinfeng Yu,Dong Wang,Xiaohui Wang,Shiyue Sun,Yuhang Zhang...&Xianjun Qu.(2019).CXCL12/CXCR4 promotes inflammation-driven colorectal cancer progression through activation of RhoA signaling by sponging miR-133a-3p.JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,38,(1)
MLA:
Xinfeng Yu,et al."CXCL12/CXCR4 promotes inflammation-driven colorectal cancer progression through activation of RhoA signaling by sponging miR-133a-3p".JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 38..1(2019):32